IT
Inherent Targeting
Trace Biosciences develops fluorescent contrast agents that specifically target nerves during surgical procedures, enhancing visualization and precision. This technology aims to improve surgical outcomes by reducing the risk of nerve damage and associated complications.
Traction 10/10Founded 2019
Portland, United States · HQ
- Biotechnology
Updated 16 days ago
Funding
Raised to date
$52.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$2.3M across 1 disclosed round
N$2.3M · Grant
Announced Mar 2021 · from article date
Disclosed cumulative: $2.3M
Reported total $52.3M
Incomplete round history. $50M of the $52.3M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Founder details are not available yet.
Product
Features
- Trace Biosciences develops fluorescent contrast agents that specifically target nerves during surgical procedures, enhancing visualization and precision. This technology aims to improve surgical outcomes by reducing the risk of nerve damage and associated complications.